This module describes the roles of the various players in the procedure, the sequence and duration of the stages involved, and the requirements on content, format and timing of submissions. It discusses the special issues that apply to generic products in the DCP.
Who will benefit from this module?
This module is primarily aimed at regulatory affairs professionals dealing with marketing authorisation applications and related submissions for regulatory approval in Europe. More generally, it will also be of interest to all those involved in the development and registration of medicinal products.
- Provide an overview of the DCP process.
- Describe the pre-submission and submission actions in relation to timeline deadlines.
- Specify the responsibilities of the Reference Member State (RMS), the Concerned Member States (CMSs) and the applicant.
CPD Points: 2
Assessment: Multiple-choice mastery assessment.
DCP Step 1 - This session takes you through the pre-procedural step and the first assessment stage of the DCP, as far as day 120.
DCP Step 2 - This session takes you through the second assessment stage and the final step of issuing national licences. Referral of issues to the CMD, and the arbitration process, are also covered.
Generics and the DCP - This session gives a brief introduction to generics and the special issues facing generics in the DCP.